Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (15823)	2/25/1998 1:29:00 AM
From: Henry Niman	Respond to of 32384

Torben, As far as I know, LGND is three for three in the patent/alliance legal arena. The settled with PFE out of court on Droloxifene. For retinoids they settled on favorable terms with SelectRA/La Jolla Cancer Institute (LGND gets to commercialize the technology) and now they have worked out an agreement with CYTL. Of course they have some very broad patents (including mine) which are infringed upon all the time. Not sure who they will go after next (although they have asked for an interference hearing against Roche which I think will be a slam dunk), but they seem to be doing a good job (their patent attorneys are Lyon and Lyon, who, if you recall, represented Hybritech in the Tandem Assay suit that went all the way to the Supreme Court (Hybritech won).